
- Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares, closed regular trading session at $3.5. The company shares are currently trading at $3.67, up 4.86 percent in the after-hours trading session.
- Halozyme Therapeutics (NASDAQ:HALO) announced that Roche's Phase III IMscin001 study evaluating a subcutaneous (SC) formulation of Tecentriq® (atezolizumab) with Halozyme's ENHANZE® technology met its co-primary endpoints. Halozyme shares traded in a range of $47.55 to $48.9 on a day volume of 1.13 million shares, closed regular trading session at $47.93.